Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
EPS (Diluted)
Shenzhen Mindray Bio-Medical Electronics Co Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
EPS (Diluted)
¥6
|
CAGR 3-Years
-5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
S
|
Shanghai MicroPort MedBot Group Co Ltd
HKEX:2252
|
EPS (Diluted)
¥0
|
CAGR 3-Years
41%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
A
|
APT Medical Inc
SSE:688617
|
EPS (Diluted)
¥5
|
CAGR 3-Years
32%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
EPS (Diluted)
¥1
|
CAGR 3-Years
11%
|
CAGR 5-Years
2%
|
CAGR 10-Years
15%
|
|
|
Andon Health Co Ltd
SZSE:002432
|
EPS (Diluted)
¥4
|
CAGR 3-Years
-50%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
EPS (Diluted)
¥1
|
CAGR 3-Years
-4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
Glance View
In the bustling city of Shenzhen, China, a thriving enterprise known as Shenzhen Mindray Bio-Medical Electronics Co., Ltd, has cemented its place within the global medical devices market. Born in 1991 amid the backdrop of China’s rapid economic expansion, Mindray embarked on an ambitious journey to revolutionize healthcare technology. The company operates across three main segments: patient monitoring and life support, in-vitro diagnostics, and medical imaging systems. Each category is crucial to the medical infrastructure, with patient monitoring systems tracking vital statistics in real-time, in-vitro diagnostics facilitating intricate lab testing, and medical imaging enabling precise internal examinations. The synergy among these segments allows Mindray to deliver comprehensive solutions that enhance both the quality and efficiency of healthcare systems worldwide. Mindray's business model is intrinsically tied to innovation and global distribution. The company continually invests in research and development, a strategic move that keeps it at the forefront of medical technology advancement. Its R&D centers — strategically located in China, the U.S., and Europe — work tirelessly to push the boundaries of medical technology and address the evolving needs of healthcare professionals. In tandem with its technological prowess, Mindray crafts a robust network of distribution that ensures its advanced devices reach hospitals and clinics across over 190 countries. This expansive market presence, coupled with competitive pricing strategies, has propelled the company to secure a formidable foothold in both emerging and developed economies, thereby transforming the accessibility and delivery of healthcare services on a global scale.
See Also
What is Shenzhen Mindray Bio-Medical Electronics Co Ltd's EPS (Diluted)?
EPS (Diluted)
6.7
CNY
Based on the financial report for Dec 31, 2025, Shenzhen Mindray Bio-Medical Electronics Co Ltd's EPS (Diluted) amounts to 6.7 CNY.
What is Shenzhen Mindray Bio-Medical Electronics Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
4%
Over the last year, the EPS (Diluted) growth was -30%. The average annual EPS (Diluted) growth rates for Shenzhen Mindray Bio-Medical Electronics Co Ltd have been -5% over the past three years , 4% over the past five years .